News Brief
Serum Institute Plans Special Vaccine For JN.1 Variant Amidst Surging Covid-19 Cases In India
Covid-19 vaccine. (representative image)
As Covid-19 cases surge in India, the Pune-based Serum Institute of India is gearing up to sell vaccines specifically targeting the new JN.1 variant.
According to a report by Business Standard, the institute is preparing to apply for licensing for the vaccine, which is currently available for the XBB1 variant and deemed "very similar" to JN.1.
The institute plans to share the necessary documents with the public once they are submitted to regulators.
Serum Institute of India, led by Adar Poonawalla, is well-known for manufacturing the Covishield vaccine, widely used during the first and second waves of the Covid-19 pandemic in India.
With the rising number of Covid-19 cases, including those related to the new JN.1 variant, the move by the Serum Institute aligns with the ongoing efforts to adapt to the evolving nature of the virus.
As of Friday (22 December), India recorded 640 fresh Covid-19 infections, with the total number of active cases standing at 2,997.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
